Drugs for Treatment of Prostate Cancer Market Future Growth, Opportunities and Forecast to 2021

Submitted by: Submitted by

Views: 10

Words: 1654

Pages: 7

Category: Business and Industry

Date Submitted: 06/15/2016 11:13 PM

Report This Essay

Global and China Drugs for Treatment of Prostate Cancer

Market Size, Share, Analysis, Forecast, Industry Strategy,

Opportunity and Challenges Report To 2021

The global Drugs for Treatment of Prostate Cancer market was valued at USD 43.47 Billion in

2015, and is projected to reach USD 52.16 Billion by 2021, at a CAGR of 9.99% between 2016

and 2021. The market is projected witness significant growth in the coming years, owing to the

aging population increase, increased incidence and development of new drugs

This report studies Drugs for Treatment of Prostate Cancer in Global market, including

Triptorelin, Leuprorelin, Flutamide Tablets, Goserelin, Bicalutamide Tablets, Bicalutamide

Capsules, Estramustine Phosphate Capsules, Mitoxantrone, Zytiga and Xtandi, focuses on price,

sales, revenue of each type in global. This report also focuses on the sales (consumption),

production, import and export of Drugs for Treatment of Prostate Cancer in America,

Established ROW, Western Europe, Emerging Markets, Russia and China, forecast to 2021,

from 2015.And Zytiga took up 51.33% market share in 2015.

On basis of segments by Types, this report focuses on price, sales, revenue and growth rate of

each type, as well as the types and each type price of key manufacturers, through interviewing

key manufacturers.

Inquire at: https://marketreportscenter.com/reports/299723/global-and-china-drugs-fortreatment-of-prostate-cancer-research-report-2015-to-2021

On basis of segments by manufacturers, this report focuses on the sales, price of each type,

average price of Drugs for Treatment of Prostate Cancer, revenue and market share, for key

manufacturers. The main manufacturers as follows: IPSEN, Ferring Pharmaceuticals, Takeda

Pharmaceutical Company Limited, Schering-Plough Canada, S.C.SINDAN-PHARMA S.R.L.,

AstraZeneca, Corden Pharma GmbH, Shanxi Zhendong Pharmaceutical, Pfizer, Johnson,

Astellas and so on.

On basis of segments by regions, this report focuses on the...